Economic Evaluation of Etoricoxib versus Non-Selective NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis Patients in the UK

摘要: Introduction: The objective of this study was to evaluate the potential economic implications using etoricoxib versus non-selective NSAID alternatives in treatment patients with osteoarthritis (OA) or rheumatoid arthritis (RA) UK. Study design: Decision-analytical modelling used calculate expected costs and consequences use compared NSAIDs alone, plus proton pump inhibitors (PPIs), histamine H2 receptor antagonists misoprostol over a continuous period 1 year. Methods: model considered direct medical from perspective UK National Health Service (NHS) data phase IIb III clinical trials determine probabilities gastrointestinal (GI) events. Model outcomes were defined as resource-consuming GI-related events, including clinically evident gastroduodenal perforations, symptomatic ulcers, upper GI bleeding (collectively, PUBs [’perforation, ulcers and/or bleeding’]). Resource utilisation (2002 values) for OA RA well events based on published literature information available UK-specific sources. Main outcome measures results: suggests that is cost saving PPIs misoprostol. also effective terms incremental per QALY gained alone (£19 766) (£9350). PUB avoided £12 446 £6438 co-prescribed antagonists. For without presence specific risk factors (history event, corticosteroid disability), may be age 56 years, assuming cost-effectiveness threshold £30 000 gained. Etoricoxib all ages who had at least one factor. Conclusions: suggests, its underlying assumptions data, cost-effective alternative therapeutic regimens involving RA, NHS perspective. dominant together PPI When antagonists, within generally accepted effectiveness (less than gained).